With Kathy High on board, AskBio makes next lead­er­ship play and se­lects Bay­er's Gu­ru Ra­ma­murthy as fi­nance chief; Myles O'Neill and Melis­sa Barnes set to re­tire from Eli Lil­ly

Gu­ru Ra­ma­murthy

→ The stars aligned to bring in Kathy High as pres­i­dent of ther­a­peu­tics, and Brain Neu­rother­a­py Bio founder Krystof Bankiewicz now leads its Parkin­son’s pro­gram. And in its first big lead­er­ship move since they signed on to the team, gene ther­a­py play­er AskBio has ap­point­ed Gu­ru Ra­ma­murthy CFO, a spokesper­son tells End­points News. Six months re­moved from strik­ing a deal to ac­quire AskBio, it should come as no sur­prise that Ra­ma­murthy is a 20-year Bay­er alum: More re­cent­ly he had been the Ger­man multi­na­tion­al’s glob­al fi­nance lead for the on­col­o­gy fran­chise, and pri­or to that, Ra­ma­murthy was CFO of the North Amer­i­can busi­ness at Bay­er Con­sumer Health.

Myles O’Neill

→ Long­time staffers Myles O’Neill (SVP and pres­i­dent of man­u­fac­tur­ing op­er­a­tions) and Melis­sa Barnes (SVP and chief ethics and com­pli­ance of­fi­cer) are re­tir­ing at Eli Lil­ly. The cur­tain clos­es for O’Neill at the In­di­anapo­lis phar­ma on May 2, while Barnes’ last day is June 27.

Melis­sa Barnes

O’Neill’s suc­ces­sor, Edgar­do Her­nan­dez, has been with Lil­ly since 2009 and will round out his tenure as SVP, glob­al par­enter­al drug prod­uct and de­vice man­u­fac­tur­ing. Alon­zo Weems, who is Lil­ly’s VP and deputy gen­er­al coun­sel, will re­place Barnes and has de­vot­ed near­ly a quar­ter-cen­tu­ry to the phar­ma gi­ant.

Alex Franzu­soff has re­tired as CEO of South San Fran­cis­co T cell biotech PACT Phar­ma, while the Scott Gar­land era of­fi­cial­ly be­gan Fri­day. Gar­land pre­vi­ous­ly helmed Por­to­la for two years un­til Alex­ion com­plet­ed its $1.4 bil­lion pur­chase of the com­pa­ny in Ju­ly 2020. Gar­land, who was with Genen­tech from 2002-11 and led sales and mar­ket­ing for Avastin and Rit­ux­an, then be­came CCO at Ex­elix­is and Re­lyp­sa, fin­ish­ing his tenure at the lat­ter as pres­i­dent of the US com­mer­cial launch of Veltas­sa.

Franzu­soff will stay on for a few more months at PACT Phar­ma in an ad­vi­so­ry ca­pac­i­ty.

Ty How­ton

Ty How­ton has re­unit­ed with CEO Bo Cum­bo to take on the roles of COO and gen­er­al coun­sel at Aa­van­tiBio. Cum­bo and How­ton’s tenures at Sarep­ta co­in­cid­ed with one an­oth­er when Cum­bo was chief com­mer­cial of­fi­cer and How­ton was a le­gal ex­ec, more re­cent­ly as the Duchenne biotech’s gen­er­al coun­sel. How­ton al­so brings ex­pe­ri­ence from Ver­tex as its chief le­gal of­fi­cer and Genen­tech as its chief health­care com­pli­ance of­fi­cer. His ap­point­ment quick­ly fol­lows that of Dou­glas Swirsky as CFO and trea­sur­er, which we had for you here last week.

John Schroer

Join­ing forces with Bris­tol My­ers Squibb on T cell ther­a­pies for sol­id tu­mors — with Bris­tol shelling out $70 mil­lion up­front — Ar­se­nal­Bio has tapped John Schroer as CFO and Tim Siri­choke as chief tech­ni­cal op­er­a­tions of­fi­cer. Schroer had been Trans­late Bio’s CFO since the spring of 2018, while Siri­choke is a No­var­tis vet who ar­rives at Ar­se­nal­Bio af­ter a stint at Genen­tech as VP of In­di­vid­u­al­ized Neo-Anti­gen Spe­cif­ic Ther­a­pies (IN­eST) man­u­fac­tur­ing.

→ Woburn, MA-based Ax­i­al Ther­a­peu­tics has pro­mot­ed Stew­art Camp­bell to the po­si­tion of CEO, suc­ceed­ing David Don­abe­di­an. Camp­bell joined the com­pa­ny in 2016, serv­ing as SVP, R&D. Pri­or to hop­ping aboard the com­pa­ny, Camp­bell held roles at An­co­ra/Cor­den­Phar­ma, Sur­face Logix and In­smed.

→ To quote Tom Pet­ty, the wait­ing was the hard­est part for Aveo On­col­o­gy, but the wait is over af­ter the FDA gave its ap­proval to tivozanib, now mar­ket­ed as Fo­tiv­da, for re­lapsed or re­frac­to­ry ad­vanced re­nal cell car­ci­no­ma. Along with that news comes the pro­mo­tion of Mike Fer­ra­res­so to chief com­mer­cial of­fi­cer, who was pre­vi­ous­ly SVP, busi­ness an­a­lyt­ics and com­mer­cial op­er­a­tions. Tak­ing the same CCO post that CEO Michael Bai­ley held when he first joined AVEO, Fer­ra­res­so’s oth­er stops in­clude Ve­rastem and AM­AG Phar­ma­ceu­ti­cals.

Gre­go­ry Wein­hoff

Centes­sa Phar­ma­ceu­ti­cals — the group of 10 sub­sidiaries pulled to­geth­er by Medicxi’s Francesco De Ru­ber­tis that al­so hand­ed the CSO reins to ex-Op­er­a­tion Warp Speed chief Mon­cef Slaouihas tapped Gre­go­ry Wein­hoff as CFO. Wein­hoff co-found­ed and was CBO and CFO of Arvelle, which got the M&A wheels turn­ing in 2021 with An­geli­ni buy­ing out the com­pa­ny for $960 mil­lion. Ad­di­tion­al­ly, Wein­hoff was CFO at Ax­o­vant from 2015-19.

Centes­sa has al­so as­sem­bled a few lu­mi­nar­ies to serve on the board of di­rec­tors: Tesaro co-founder and ex-pres­i­dent Mary Lynne Hed­ley, for­mer FDA com­mis­sion­er Robert Califf and CRISPR Ther­a­peu­tics CEO Sam Kulka­rni were all named to the board Feb. 23.

Pe­ony Yu

→ Af­ter re­tir­ing from Fi­bro­Gen — which is once again in rox­adu­s­tat lim­bo fol­low­ing an­oth­er de­lay — in De­cem­ber, Pe­ony Yu is back on the CMO block with im­muno-on­col­o­gy play­er Apol­lomics start­ing this com­ing Tues­day. She re­places in­ter­im CMO Glenn Michel­son and spent 12 years with Fi­bro­Gen, get­ting pro­mot­ed to CMO in 2016. Else­where at Or­biMed-backed Apol­lomics, So­phie (Zhengjie) Sun has been named SVP, cor­po­rate de­vel­op­ment. Sun was VP and man­ag­ing di­rec­tor of Mer­ck KGaA’s In­no­va­tion Hub Chi­na and had served at the Ger­man phar­ma in var­i­ous posts since 2009.

In­ter­cept has sad­dled up to their reg­u­lar Peer Re­view barstool with the de­par­ture of CFO Sandip Ka­pa­dia. For those scor­ing at home, CEO Mark Pruzan­s­ki, CMO Ja­son Cam­pagna and now CFO Ka­pa­dia are all gone from the C-suite af­ter the FDA’s re­jec­tion of obeti­cholic acid in June, which prompt­ed a heat­ed re­sponse from Pruzan­s­ki at the time. The con­stant flux in In­ter­cept’s lead­er­ship con­tin­ued a few weeks ago with the ap­point­ment of chief com­mer­cial of­fi­cer Lin­da Richard­son, and now it’s Ka­pa­dia’s turn af­ter near­ly five years with the com­pa­ny. In the wake of Ka­pa­dia’s ex­it, In­ter­cept’s cor­po­rate con­troller Roc­co Venezia lands the dual roles of act­ing CFO and chief ac­count­ing of­fi­cer.

Ja­son Cam­pagna

→ One of those In­ter­cept de­fec­tors, Ja­son Cam­pagna, has of­fi­cial­ly moved on to be­come CMO of Q32 Bio, which net­ted $60 mil­lion in Se­ries B fund­ing in late Oc­to­ber as the biotech looks to strength­en its com­ple­ment drug pipeline. Cam­pagna, who start­ed out as In­ter­cept’s SVP and glob­al NASH lead in 2016 be­fore slid­ing in­to the CMO slot, was al­so an ex­ec with The Med­i­cines Com­pa­ny. Our Max Gel­man dis­cussed the cof­fee meet­ings Cam­pagna had with CEO Mike Brox­son lead­ing up to the ap­point­ment since they live in such close prox­im­i­ty — “We could prob­a­bly throw a rock at each oth­er’s hous­es,” Cam­pagna said.

Lu­ca Rastel­li has joined can­cer- and au­toim­mune dis­ease-fo­cused Ju­bi­lant Ther­a­peu­tics out of Bed­min­ster, NJ as CSO af­ter near­ly three years in the same po­si­tion at Kleo Phar­ma­ceu­ti­cals. The ex-EMD Serono staffer who led de­vel­op­ment of the ap­proved MET in­hibitor Tep­metko has al­so been VP, on­col­o­gy at BioX­cel.

→ Part­ing ways with Sanofi af­ter 19 years, Anne Da­gal­li­er has signed on to Paris-based mi­cro­bio­me biotech En­terome as CBO. Lead­ing up to this change in venue, Da­gal­li­er had been head of con­sumer health care al­liances and in-li­cens­es at Sanofi Glob­al Al­liances Man­age­ment. For a time she was al­so head of ex­ter­nal in­no­va­tion, in­fec­tious dis­eases in ad­di­tion to her var­ied strate­gic and BD roles at the phar­ma gi­ant.

Ed­uar­do Bruno Mar­tins

→ San Ma­teo, CA-based Sagimet Bio­sciences has reeled in Ed­uar­do Bruno Mar­tins as CMO. Most re­cent­ly, Mar­tins served as VP of clin­i­cal de­vel­op­ment at Ab­b­Vie. Pri­or to that, Mar­tins was VP of clin­i­cal de­vel­op­ment at Al­ler­gan. In ad­di­tion, Mar­tins has served in roles at Gilead, Genen­tech, Dy­navax Tech­nolo­gies and In­ter­mune among oth­ers.

→ Last week, Gainesville, FL biotech Cy­clo Ther­a­peu­tics reeled in ex-Ed­i­tas Med­i­cine CMO Ger­ald Cox as CMO. This week, the com­pa­ny has brought on Russ Belden as act­ing CCO. Belden jump-start­ed his ca­reer at Genen­tech’s SSF Com­mer­cial or­ga­ni­za­tion, spend­ing 16 years on board. Af­ter­wards, Belden be­came the founder, pres­i­dent and CEO of Bridge Con­sult­ing. In ad­di­tion, Belden cur­rent­ly serves as the iC­CO at three Phase III com­pa­nies.

Er­mi­um Ther­a­peu­tics — fo­cused on de­vel­op­ing ther­a­pies for au­to-im­mune dis­eases — has made a new ad­di­tion to its ex­ec­u­tive team with the ap­point­ment of An­negret Van der Aa as CSO and chief de­vel­op­ment of­fi­cer. Van der Aa brings ex­pe­ri­ence with her from her time at Gala­pa­gos, Inno­genet­ics, Ac­to­GeniX and OC­TIMET On­col­o­gy.

Teona John­son

→ Stock­holm-based Cal­lid­i­tas, “de­light­ed” with its strong Phase III da­ta for Ne­fe­con last fall to use CEO Renée Aguiar-Lu­can­der’s word, has hit a tri­fec­ta of ap­pointees for its US or­ga­ni­za­tion with War­ren Brooks (VP of US med­ical af­fairs), Teona John­son (head of US mar­ket­ing) and David Fer­raro (head of US sales). Brooks leaves Len Schleifer’s folks at Re­gen­eron af­ter 12 years at sev­er­al posts, most re­cent­ly as se­nior di­rec­tor, na­tion­al lead in im­munol­o­gy in med­ical af­fairs. Since 2010, John­son held mul­ti­ple roles at Pfiz­er, break­ing from the phar­ma gi­ant af­ter lead­ing the mar­ket­ing strat­e­gy for Ibrance as glob­al com­mer­cial di­rec­tor. And Fer­raro hails from Ky­owa Kirin, where he served as na­tion­al sales di­rec­tor for the on­col­o­gy/rare dis­ease busi­ness unit.

Car­o­line Kurtz

Syn­log­ic has made some changes in its lead­er­ship team with the pro­mo­tions of Car­o­line Kurtz to chief de­vel­op­ment of­fi­cer and pro­mo­tion of Daniel Rosan to SVP and head of fi­nance. Kurtz joined Syn­log­ic in Oc­to­ber 2016. Pri­or to hop­ping aboard the com­pa­ny, Kurtz was at Iron­wood Phar­ma­ceu­ti­cals. Mean­while, Rosan joined Syn­log­ic from Bio­gen, where he held a six-year stint.

In ad­di­tion to the two pro­mo­tions, the Cam­bridge, MA-based com­pa­ny has ap­point­ed Jamie Austin as VP and in­com­ing head of reg­u­la­to­ry af­fairs. Austin comes aboard with ex­pe­ri­ence from her time at As­traZeneca, Ab­b­Vie and blue­bird bio.

→ For­mer as­sis­tant White House coun­sel Alexan­der Nguyen has stepped in as gen­er­al coun­sel at Uni­ty Biotech­nol­o­gy, which has seen its share of trou­bles and high-pro­file ex­its. Nguyen, who was on the White House le­gal team from 2010-11, has ex­pe­ri­ence at three sep­a­rate Vants to his cred­it: first as head of le­gal at Ax­o­vant, then as head of com­pli­ance at Roivant, and fi­nal­ly as gen­er­al coun­sel at Aly­vant.

As­cen­sion Health­care — fo­cused on ther­a­pies for he­mo­phil­ia and os­teoarthri­tis — has named Ben Ver­tannes as head of glob­al mar­ket­ing. Ver­tannes joins the com­pa­ny with ex­pe­ri­ence from his roles at Bay­er, No­var­tis, Wella and Pfiz­er.

Bar­bara Kosacz

Bar­bara Kosacz has made her way to the board of di­rec­tors at Leen Kawas-led Athi­ra Phar­ma not long af­ter be­com­ing a board mem­ber at Ar­se­nal­Bio. Peer Re­view cov­ered Kosacz’s ap­point­ment as COO and gen­er­al coun­sel of Kro­nos Bio last sum­mer.

→ Stan­ford Uni­ver­si­ty School of Med­i­cine pro­fes­sor (and not­ed Eliz­a­beth Holmes skep­tic) Phyl­lis Gard­ner has jumped on to the board of di­rec­tors at MiMedx. Since 2006, Gard­ner has al­so been a board mem­ber at Re­vance.

Ner­is­sa Kre­her

→ Sil­i­con Val­ley-based Re­zo­lute, work­ing on its lead drug RZ358 to treat con­gen­i­tal hy­per­in­sulin­ism, has se­lect­ed Vlad Hogen­huis and Ner­is­sa Kre­her for its board of di­rec­tors. Hogen­huis, a GSK vet, is the ex-COO of Ul­tragenyx, while Kre­her was just ap­point­ed CMO of En­tra­da Ther­a­peu­tics a few months ago.

Su­san Wind­ham-Ban­nis­ter

→ On clin­i­cal hold with its knee car­ti­lage re­gen­er­a­tion ther­a­py, His­to­gen out of San Diego has ap­point­ed Su­san Wind­ham-Ban­nis­ter to the board of di­rec­tors. Wind­ham-Ban­nis­ter, the pres­i­dent and CEO of Bio­med­ical Growth Strate­gies, is al­so the found­ing pres­i­dent and CEO of the Mass­a­chu­setts Life Sci­ences Cen­ter.

→ Lon­don-based Free­line Ther­a­peu­tics, which hit the pause but­ton last month on its gene ther­a­py tri­al, has brought in Col­in Love to be a mem­ber of the board of di­rec­tors. The Am­gen vet co-found­ed and is COO of Replimune.

Eliz­a­beth Garo­fa­lo

Tim Wal­bert-chaired gene ex­pres­sion biotech Ex­i­cure has wel­comed Eliz­a­beth Garo­fa­lo and An­drew Sas­sine to the board of di­rec­tors fol­low­ing the ap­point­ment of James Su­lat last month. Garo­fa­lo — who’s on the board at Aca­dia — was No­var­tis’ SVP and glob­al head of clin­i­cal de­vel­op­ment, and Sas­sine is CFO at Arc­turus.

Un­learn, de­vel­op­er of the first ma­chine-learn­ing plat­form that cre­ates Dig­i­tal Twins used to en­able small­er, faster clin­i­cal tri­als, has pulled in Ann E. Tay­lor to its board of di­rec­tors. Tay­lor cur­rent­ly serves as CMO of As­traZeneca. Pri­or to her role at As­traZeneca, Tay­lor was VP, glob­al clin­i­cal de­vel­op­ment at Med­im­mune and had stints at No­var­tis and Pfiz­er.

An­drew Sin­clair now has a seat re­served on the board of di­rec­tors at Adicet Bio. Sin­clair is a part­ner and port­fo­lio man­ag­er at Abing­worth and is in his 13th year with the group.

→ De­vel­op­ing ther­a­pies to re­pair dam­aged tis­sues, Pitts­burgh-based Noveome Ther­a­peu­tics has cho­sen Christo­pher Velis to join its board of di­rec­tors. Velis is the co-founder and ex­ec­u­tive chair­man of Mi­ra­ki In­no­va­tion, BOA Bio­med­ical and Arc­tic Fox Bio­med­ical. In ad­di­tion, Velis is the co-founder of Au­ris Health.

Dana Rol­li­son

NanoS­tring Tech­nolo­gies has made two new board ap­point­ments with the ad­di­tions of Dana Rol­li­son and Janet George. Rol­li­son cur­rent­ly serves as VP, chief da­ta of­fi­cer and as­so­ciate cen­ter di­rec­tor of da­ta sci­ence for the Mof­fitt Can­cer Cen­ter. Mean­while, George is the VP of au­tonomous en­ter­prise, ad­vanced an­a­lyt­ics with ma­chine learn­ing and ar­ti­fi­cial in­tel­li­gence at Or­a­cle. Pri­or to Or­a­cle, George has held stints at San­disk, Ya­hoo, eBay and Ap­ple among oth­ers.

→ La Jol­la, CA-based Arte­lo Bio­sciences has added Tama­ra Sey­mour to its board of di­rec­tors. Sey­mour pre­vi­ous­ly served in roles at Im­mu­nic, Sig­nal Ge­net­ics, De­loitte and Bea­con Dis­cov­ery, among oth­ers.

→ Ad­vanced can­cers-fo­cused Pen­rose Ther­a­peuTx has added mi­to­chon­dr­i­al re­searcher Navdeep Chan­del to its sci­en­tif­ic ad­vi­so­ry board. Chan­del is pro­fes­sor of med­i­cine bio­chem­istry and mol­e­c­u­lar ge­net­ics at North­west­ern Uni­ver­si­ty’s Fein­berg School of Med­i­cine.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may remember that at the beginning of this year, Endpoints News set a goal to go broader and deeper. We are still working towards that, and are excited to share that Beth Snyder Bulik will be joining us on Monday to cover all things pharma marketing. You can sign up for her weekly Endpoints MarketingRx newsletter in your reader profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,700+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

During our recent European Biopharma Summit, I talked with Novartis development chief John Tsai about his experiences over the 3-plus years he’s been at the pharma giant. You can read the transcript below or listen to the exchange in the link above.

John Carroll: I followed your career for quite some time. You’ve had more than 20 years in big pharma R&D and you’ve obviously seen quite a lot. I really was curious about what it was like for you three and a half years ago when you took over as R&D chief at Novartis. Obviously a big move, a lot of changes. You went to work for the former R&D chief of Novartis, Vas Narasimhan, who had his own track record there. So what was the biggest adjustment when you went into this position?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing expertise in lung cancer. The drug will now take an early lead in the sought-after adjuvant setting — but competitors are on the way.

The FDA on Friday approved Tecentriq as an adjuvant therapy for patients with Stage II-IIIA non small cell lung cancer with PD-(L)1 scores greater than or equal to 1, making it the first drug of its kind approved in an early setting that covers around 40% of all NSCLC patients.

Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a breakthrough.

The Stanford neurologist, a soft-spoken demi-prodigy who became a professor while still a resident, had been obsessed for a decade with how to better define psychiatric disorders. Drugs for depression or bipolar disorder didn’t work for many patients with the conditions, and he suspected the reason was how traditional diagnoses didn’t actually get at the heart of what was going on in a patient’s brain.

Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'

 

Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Tillman Gerngross, Adagio CEO

Q&A: Till­man Gern­gross ex­plains why his Covid mAb will have an edge over an al­ready crowd­ed field

If anyone knows about monoclonal antibodies, it’s serial entrepreneur, Adimab CEO, and Dartmouth professor of bioengineering Tillman Gerngross.

Even the name of Gerngross’ new antibody startup Adagio Therapeutics is meant to reflect his vision behind the development of his Covid-19 mAb: slowly, he said, explaining that “everyone else, whether it’s Regeneron, Lilly, or AstraZeneca, Vir, they all valued speed over everything.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Susan Galbraith speaking at Endpoints News' virtual EUBIO21 summit

Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

Is the tide turning on AstraZeneca’s battered PD-L1/CTLA4 combo?

A single priming dose of the experimental tremelimumab, followed by Imfinzi every four weeks, beat Nexavar (sorafenib) in helping a group of liver cancer patients live longer in a Phase III study, the company reported, meeting the primary endpoint.

Specifically, the two drugs extended overall survival for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,700+ biopharma pros reading Endpoints daily — and it's free.

Lu­ba Green­wood takes the helm at Ko­jin Ther­a­peu­tics, steer­ing an all-fe­male C-suite; Alex­ion R&D chief packs up for change of scenery at VC firm

How rare is it to find a woman leading a micro- or small-cap biotech company? According to a recent survey, it happens less than 6% of the time. And all-female C-suites? Almost unheard of.

But on Thursday, Kojin Therapeutics officially tapped Luba Greenwood as its first CEO, completing an all-female C-suite. All of the biotech’s senior scientists are women too, as is the scientific co-founder. It’s a moment that Greenwood always believed would come.